DenmarkDenmark

Santaris Pharma to raise EUR 12.5m

22.11.2007

Hamburg – Santaris Pharma A/S aims to close a Serie C financing round valued at a12.5 million in November/December. As the company announced during its pre-sentation in the framework of the BioEurope partnering conference held in Hamburg, Germany, from 12th to 14th October, negotiations with four investors are ongoing. Horsholm-based company Santaris Pharma was established in 2003 through the merger of the two biotech companies Pantheco A/S and Cureon A/S. The major focus of the company is to develop drug candidates based on Locked Nucleic Acid (LNA). One of the lead products (spc2996) is an Bcl-2 mRNA antagonist for the treatment of chronic lymphocytic leukaemia, with which an optimised second phase I/II began in Q1 2007. In 2006, the company raised a40 million.

DenmarkDenmark

19.08.2011

Bagsværd – Net profit at Denmark’s Novo Nordisk A/S ballooned in the first six months of 2011, and the firm has raised guidance for the full year results. Sales rose by 9%, from DKK29.1bn to DKK31.7bn, while reported net profit...

DenmarkDenmark

15.08.2011

Copenhagen – Driven by strong sales, Danish drugmaker Lundbeck A/S reported hefty QII/2011 profits, and says it is now expecting full-year results at the upper end of its guided range. Operating profit rose to DKK1.1bn in the...

DenmarkDenmark

12.08.2011

Copenhagen - All is well in Denmark - for now. Danish Drugmaker Lundbeck reported excellent profits in the second quarter but announced its intention to prepare for deep cuts in research. 175 jobs in Denmark and the US (12.5% of...

DenmarkDenmark

06.06.2011

Kvistgaard – Bavarian Nordic A/S of Denmark has raised DKK698m (EUR94m)through a rights issue to fund development of its prostate cancer vaccine Prostvac. A total of 12.9 million shares were sold at DKK54. The company announced...

DenmarkDenmark

12.04.2011

Kvistgaard – Net loss at Danish biopharmaceutical company Bavarian Nordic A/S increased to DKK390m from DKK266m in the previous year, even though revenue grew to DKK314m, up from DKK75m in 2009. Bavarian Nordic’s lead product is...

DenmarkDenmark

09.04.2011

Copenhagen – Despite recent setbacks, Danish TopoTarget A/S still has hopes for its histone deacetylase (HDAc) blocker belinostat (PXD01). The cytotoxic compound for treating lymphoma and solid tumours has failed to show...

Displaying results 11 to 20 out of 194

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/1/article/santaris-pharma-to-raise-eur-125m.html

Stock list

All quotes

TOP

  • SERODUS (N)3.05 NOK7.02%
  • SILENCE THERAPEUTICS (UK)244.75 GBP4.15%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ALMIRALL (E)11.07 EUR-7.13%

TOP

  • SANTHERA (CH)70.65 CHF114.1%
  • ADDEX (CH)4.54 CHF108.3%
  • CELLECTIS (F)13.54 EUR103.6%

FLOP

  • THROMBOGENICS (B)8.51 EUR-52.2%
  • MERCK KGAA (D)63.67 EUR-50.6%
  • VERONA PHARMA (UK)1.20 GBP-43.4%

TOP

  • SANTHERA (CH)70.65 CHF3111.4%
  • GW PHARMACEUTICALS (UK)443.50 GBP843.6%
  • PAION (D)2.71 EUR310.6%

FLOP

  • CYTOS (CH)0.24 CHF-93.1%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 11.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events